Literature DB >> 7952612

Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes.

J Rello1, A Torres, M Ricart, J Valles, J Gonzalez, A Artigas, R Rodriguez-Roisin.   

Abstract

All episodes of ventilator-associated pneumonia (VAP) caused by Staphylococcus aureus were prospectively analyzed for a 30-mo period. Methicillin-sensitive S. aureus (MSSA) was isolated in 38 episodes and methicillin-resistant S. aureus (MRSA) in 11 others. The two groups were similar regarding sex, severity of underlying diseases, prior surgery, and presence of renal failure, diabetes, cardiopathy, and coma. MRSA-infected persons were more likely to have received steroids before developing infection (relative risk [RR] = 3.45, 95% confidence interval [CI] = 1.38-8.59), to have been ventilated > 6 d (RR = 2.03, 95% CI = 1.36-3.03), to have been older than 25 yr (RR = 1.50, 95% CI = 1.09-2.06), and to have had preceding chronic obstructive pulmonary disease (RR = 2.76, 95% CI = 0.89-8.56) than MSSA-infected patients. MSSA-infected persons were more likely than MRSA-infected patients to have cranioencephalic trauma (RR = 1.94, 95% CI = 1.22-3.09). All patients with MRSA VAP had previously received antibiotics, compared with only 21.1% of those with MSSA infection (p < 0.000001). The incidence of empyema was similar in both groups; nevertheless, the presence of bacteremia and septic shock was more frequent in the MRSA group. Finally, mortality directly related to pneumonia was significantly higher among patients with MRSA episodes (RR = 20.72, 95% CI = 2.78-154.35). This analysis was repeated for monomicrobial episodes, and the difference remained statistically significant. We conclude that MRSA and MSSA strains infect patients with different demographic profiles; previous antibiotic therapy is the most important risk factor for developing MRSA infection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952612     DOI: 10.1164/ajrccm.150.6.7952612

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  67 in total

1.  Pulmonary disposition of vancomycin in critically ill patients.

Authors:  H Georges; O Leroy; S Alfandari; B Guery; M Roussel-Delvallez; C Dhennain; G Beaucaire
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

2.  Distribution of mecA among methicillin-resistant clinical staphylococcal strains isolated at hospitals in Naples, Italy.

Authors:  E Galdiero; G Liguori; M D'Isanto; N Damiano; L Sommese
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

3.  Linezolid in VAP by MRSA: a better choice?

Authors:  Malina Ioanas; Hartmut Lode
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

Review 4.  Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit.

Authors:  A S Haddadin; S A Fappiano; P A Lipsett
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

5.  Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria.

Authors:  Elpis Giantsou; Nikolaos Liratzopoulos; Eleni Efraimidou; Maria Panopoulou; Eleonora Alepopoulou; Sofia Kartali-Ktenidou; George I Minopoulos; Spyros Zakynthinos; Konstantinos I Manolas
Journal:  Intensive Care Med       Date:  2005-09-07       Impact factor: 17.440

6.  Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.

Authors:  Pieter Depuydt; Dominique Benoit; Dirk Vogelaers; Geert Claeys; Gerda Verschraegen; Koenraad Vandewoude; Johan Decruyenaere; Stijn Blot
Journal:  Intensive Care Med       Date:  2006-09-16       Impact factor: 17.440

7.  A new category--healthcare-associated pneumonia: a good idea, but problems with its execution.

Authors:  S Fujitani; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-10       Impact factor: 3.267

8.  Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.

Authors:  John A Bosso; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

9.  Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.

Authors:  Thomas P Lodise; Peggy S McKinnon; Donald P Levine; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

10.  Outcome of ventilator-associated pneumonia: Impact of antibiotic therapy and other factors.

Authors:  Noyal Mariya Joseph; Sujatha Sistla; Tarun Kumar Dutta; Ashok Shankar Badhe; Desdemona Rasitha; Subhash Chandra Parija
Journal:  Australas Med J       Date:  2012-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.